Clinical trial
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
NCT00130689 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00130689 |
|---|---|
| Title | Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer |
| Official title | A Phase II Trial of Cetuximab in Unresectable or Metastatic Esophageal and Gastric Carcinoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Bristol-Myers Squibb Industry Massachusetts General Hospital Beth Israel Deaconess Medical Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Cetuximab |
| Enrollment | 43 |
| Start date | Jul 1, 2005 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Aug 16, 2005 |
| Last update posted | May 14, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: